16 September 2026 editorial review · Item
CT-868 (acmopatide): review notes
These notes document the scope actually reviewed, including source-access limits. They are not independent clinical certification or a guarantee that every claim was verified.
Read the item evidence page →Thriving evidence review — 16 September 2026
Record: CT-868 (acmopatide)
Scope and findings:
- Corrected primary PDF table misreading: removed from phase II, not new to phase III. Development discontinued; maturity/access editorial scores reduced from 52/5 to 35/0 to match evidence/access. Conference outcomes not newly independently validated.
Primary sources checked:
Limits: The review is restricted to the scopes above. Historical efficacy estimates, editorial scoring and country-specific access were not fully reverified unless expressly stated. A manufacturer or conference report retains that evidence level.